ACAD
36.55
+0.49
+1.36%
AEMD
6.26
+0.14
+2.2892%
APRI
0.334
-0.006
-1.7378%
ARNA
1.68
-0.1
-5.62%
ATEC
0.39
+0.03
+8.33%
CNAT
2.2
+0.01
+0.46%
CRXM
0.18
0.00
0.00%
CYTX
2.03
-0.02
-0.98%
DXCM
87.89
+3.26
+3.85%
GNMK
9.8
+0.25
+2.62%
HALO
9.24
-0.11
-1.18%
ILMN
150.76
-0.55
-0.36%
INNV
0.44
+0.04
+9.73%
INO
9.13
+0.08
+0.88%
ISCO
1.945
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
132.55
+0.59
+0.45%
LPTN
2.1
+0.19
+9.95%
MBVX
0.675
+0.045
+7.143%
MEIP
1.37
-0.02
-1.44%
MNOV
6.48
-0.2
-2.99%
MRTX
5.08
-0.01
-0.20%
MSTX
0.439
+0.028
+6.709%
NBIX
49.51
+0.43
+0.88%
NUVA
61.54
-0.37
-0.60%
ONCS
1.74
+0.04
+2.35%
ONVO
4.06
+0.04
+1.00%
OREX
3.51
0.00
0.00%
OTIC
14.8
+0.13
+0.89%
QDEL
19.54
-0.09
-0.46%
RCPT
231.96
0.00
0.00%
RGLS
3.43
+0.01
+0.29%
RMD
65.93
+0.04
+0.06%
SCIE
0.004
0.00
-5.1282%
SPHS
4.38
+0.42
+10.61%
SRNE
6.3
0.00
0.00%
TROV
5.04
-0.04
-0.79%
VICL
4.03
-0.35
-7.99%
VOLC
18
0.00
0.00%
ZGNX
8.62
-0.04
-0.46%
ACAD
36.55
+0.49
+1.36%
AEMD
6.26
+0.14
+2.2892%
APRI
0.334
-0.006
-1.7378%
ARNA
1.68
-0.1
-5.62%
ATEC
0.39
+0.03
+8.33%
CNAT
2.2
+0.01
+0.46%
CRXM
0.18
0.00
0.00%
CYTX
2.03
-0.02
-0.98%
DXCM
87.89
+3.26
+3.85%
GNMK
9.8
+0.25
+2.62%
HALO
9.24
-0.11
-1.18%
ILMN
150.76
-0.55
-0.36%
INNV
0.44
+0.04
+9.73%
INO
9.13
+0.08
+0.88%
ISCO
1.945
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
132.55
+0.59
+0.45%
LPTN
2.1
+0.19
+9.95%
MBVX
0.675
+0.045
+7.143%
MEIP
1.37
-0.02
-1.44%
MNOV
6.48
-0.2
-2.99%
MRTX
5.08
-0.01
-0.20%
MSTX
0.439
+0.028
+6.709%
NBIX
49.51
+0.43
+0.88%
NUVA
61.54
-0.37
-0.60%
ONCS
1.74
+0.04
+2.35%
ONVO
4.06
+0.04
+1.00%
OREX
3.51
0.00
0.00%
OTIC
14.8
+0.13
+0.89%
QDEL
19.54
-0.09
-0.46%
RCPT
231.96
0.00
0.00%
RGLS
3.43
+0.01
+0.29%
RMD
65.93
+0.04
+0.06%
SCIE
0.004
0.00
-5.1282%
SPHS
4.38
+0.42
+10.61%
SRNE
6.3
0.00
0.00%
TROV
5.04
-0.04
-0.79%
VICL
4.03
-0.35
-7.99%
VOLC
18
0.00
0.00%
ZGNX
8.62
-0.04
-0.46%
Home » Archive by Category

Xconomy

Frazier Enlists Three Laguna Pharma Execs to Scout for New Drugs

January 11, 2016 – 10:01 pm

Like a phoenix rising from the shutdown of San Diego’s Laguna Pharmaceuticals, former Laguna CEO Bob Baltera and two other ex-Laguna executives are now roosting under the wing of Menlo Park, CA-based…

[[Click headline to continue reading.]]

Illumina Forms Grail in Quest for Ultimate Cancer Diagnostic

January 10, 2016 – 8:24 pm

Illumina (NASDAQ: ILMN), the San Diego-based pioneer in gene-sequencing technology, says it has formed a new company called Grail to advance the sensitivity of technology already being used to detect…

[[Click headline to continue reading.]]

West Coast Bio Roundup: Big Waves, Big Cash & a Deep Pre-JPM16 Breath

January 8, 2016 – 3:50 pm

I’d say this week was the calm before the J.P. Morgan storm, except that we on the West Coast have had plenty of storms this week. Perhaps not tornadoes, but weather big enough to churn up 50…

[[Click headline to continue reading.]]

With $100M, Guardant Health to Expand Reach of Blood Test for Cancer

January 7, 2016 – 5:30 am

We’ve all heard that dust is at least partly made up of dead skin cells. However true or untrue that may be, living tissue that is growing rapidly, such as a cancerous solid tumor, does indeed shed…

[[Click headline to continue reading.]]

From Ambitions To Markets: Richard Kitney And More Synthetic Bio Views

January 6, 2016 – 4:30 am

Last week, Xconomy ran the first part of my conversation with Richard Kitney, a bioengineering professor at Imperial College London and a pioneer in the field of synthetic biology. We met in his…

[[Click headline to continue reading.]]

NuVasive Buys Skeletal Specialist in First Deal under New CEO

January 5, 2016 – 6:55 pm

San Diego’s NuVasive (NASDAQ: NUVA), a medical device maker that specializes in spinal procedures, said today it is acquiring privately held Ellipse Technologies for $380 million in cash, with an…

[[Click headline to continue reading.]]

Formerly Atterocor, Millendo Changes Name, Strategy—And Nabs $62M

January 5, 2016 – 5:00 am

When a biotech company with one product in development misses its milestones, investors typically don’t throw more money at it. Not so with the newly renamed Millendo Therapeutics. The Ann…

[[Click headline to continue reading.]]

Oncology’s Future: Liquid Biopsies and the Heterogeneity of Cancer

January 5, 2016 – 2:00 am

We have known for some time that cancer is not a static, monolithic disease. Instead, we now think of cancer as heterogeneous. Each patient’s cancer may arise from widely dissimilar origins, even in…

[[Click headline to continue reading.]]

Lab Space on a Navy Ship, And Other Creative Solutions for NY Biotech

January 4, 2016 – 10:01 pm

I was a management consultant in a former life, and was trained in that role to always have three arguments to support any conclusion. But having spent the last six months living and breathing…

[[Click headline to continue reading.]]

Synthetic Biology Primer: In Conversation With Richard Kitney, Part 1

December 31, 2015 – 3:00 am

“Synthetic biology” has always been a puzzling term to me. Prosthetic limbs are synthetic. Knee replacements are synthetic. Splicing the gene from one organism into another, a practice…

[[Click headline to continue reading.]]